Home・Lista de Ações・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Abrir

SetorSaúde

230.41 -0.92

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

227.96

Máximo

232.65

Indicadores-chave
By Trading Economics
Rendimento	262M -15M
Vendas	1.6M 996M
EPS	2.06
Margem de lucro	-1.486
Funcionários	18,300
EBITDA	-135M 64M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	-0.99% downside

Dividendos
By Acuity
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.4B 11B
Abertura anterior	231.33
Fecho anterior	230.41

Sentimento de Notícias

By Acuity

28%

72%

66 / 340 Ranking em Healthcare

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de jul. de 2026, 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30 de jul. de 2026, 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29 de jul. de 2026, 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

28 de jul. de 2026, 18:02 UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

27 de jul. de 2026, 17:36 UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

23 de jul. de 2026, 00:01 UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

22 de jul. de 2026, 22:01 UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

21 de jul. de 2026, 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20 de jul. de 2026, 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

-0.99% parte inferior

Previsão para 12 meses

Média 230.2 USD -0.99%

Máximo 265 USD

Mínimo 213 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

66 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.